We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

143 hedge funds and large institutions have $1.47B invested in Epizyme, Inc in 2020 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 52 increasing their positions, 47 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

888% more call options, than puts

Call options by funds: $47.9M | Put options by funds: $4.84M

41% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 22

11% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 47

5% more funds holding

Funds holding: 136143 (+7)

10% less funds holding in top 10

Funds holding in top 10: 109 (-1)

35% less capital invested

Capital invested by funds: $2.25B → $1.47B (-$781M)

Holders
143
Holders Change
+7
Holders Change %
+5.15%
% of All Funds
3.15%
Holding in Top 10
9
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-10%
% of All Funds
0.2%
New
31
Increased
52
Reduced
47
Closed
22
Calls
$47.9M
Puts
$4.84M
Net Calls
+$43M
Net Calls Change
-$33.4M

EPZM Hedge Fund Activity: Q1 2020 in Review

143 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q1 2020, worth a combined $1.47B — down 35% from $2.25B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new EPZM positions and 22 closed out — a net gain of 9 holders — while 52 added to existing stakes and 47 trimmed.

The largest buyer was RP Management, adding an estimated $53.7M. The largest seller was Opaleye Management, exiting entirely with an estimated $34.1M sold.

  • 143 institutional investors held Epizyme, Inc (EPZM) as of Q1 2020, up from 136 in Q4 2019.
  • Funds reported $1.47B of Epizyme, Inc stock for Q1 2020, down 35% quarter-over-quarter.
  • 31 funds opened new Epizyme, Inc positions in Q1 2020 and 22 closed out, a net change of +9 holders.
  • The largest Epizyme, Inc buyer in Q1 2020 was RP Management, an estimated $53.7M added.
  • The largest Epizyme, Inc seller in Q1 2020 was Opaleye Management, an estimated $34.1M sold.

Based on aggregated 13F filings for Q1 2020.